JPMorgan Chase & Co. Sells 80,013 Shares of ICU Medical, Inc. $ICUI

JPMorgan Chase & Co. decreased its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 10.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 676,370 shares of the medical instruments supplier’s stock after selling 80,013 shares during the quarter. JPMorgan Chase & Co. owned 2.74% of ICU Medical worth $81,137,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ICUI. Bryce Point Capital LLC acquired a new position in ICU Medical in the third quarter worth about $586,000. Inscription Capital LLC lifted its stake in ICU Medical by 407.9% during the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock worth $1,003,000 after purchasing an additional 6,718 shares during the period. Federated Hermes Inc. boosted its holdings in ICU Medical by 56.5% during the third quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock valued at $34,823,000 after purchasing an additional 104,798 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in shares of ICU Medical in the 3rd quarter valued at approximately $1,096,000. Finally, Public Sector Pension Investment Board grew its stake in shares of ICU Medical by 14.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 96,270 shares of the medical instruments supplier’s stock valued at $11,549,000 after purchasing an additional 12,412 shares during the period. 96.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday, February 15th. Piper Sandler upped their price target on ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Finally, KeyCorp lifted their price objective on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $179.33.

ICU Medical Stock Performance

NASDAQ ICUI opened at $125.29 on Thursday. ICU Medical, Inc. has a 1-year low of $107.00 and a 1-year high of $160.29. The company has a 50 day moving average of $146.73 and a 200-day moving average of $138.09. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of 6,267.63, a PEG ratio of 1.88 and a beta of 0.79.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 EPS for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The business had revenue of $535.94 million for the quarter, compared to the consensus estimate of $541.20 million. During the same period in the previous year, the business earned $2.11 EPS. ICU Medical’s revenue was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, equities analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.